Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag

HIV-associated thrombocytopenia is a dis- ease which can be recurrent to standard therapy which includes highly active antiretroviral therapy (HAART) therapy, steroids and immunoglobulin. We report a patient with HIV and hepatitis C who presented with resistant thrombocytopenia. Treatment with Eltrombopag – a thrombopoeitin receptor agonist showed initial good response with recurrence of thrombocytopenia. This novel agent could be considered as a treatment option prior to splenectomy and may be useful as a tempo- rizing measure.

Download Full-text

Faculty Opinions recommendation of HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1040117.489034 ◽

2006 ◽

Author(s):

Anthony Harries

Keyword(s):

Antiretroviral Therapy ◽

North America ◽

Treatment Response ◽

Highly Active Antiretroviral Therapy ◽

Hiv Treatment ◽

Highly Active ◽

Collaborative Analysis

Download Full-text

Faculty Opinions recommendation of Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1092834.547765 ◽

2007 ◽

Author(s):

Juergen Rockstroh

Keyword(s):

Human Immunodeficiency Virus ◽

Hepatitis C Virus ◽

Liver Disease ◽

Hepatitis C ◽

Antiretroviral Therapy ◽

Chronic Liver Disease ◽

Highly Active Antiretroviral Therapy ◽

Clinical Progression ◽

Highly Active ◽

Immunodeficiency Virus

Download Full-text

Graves' Disease as a Manifestation of Immune Reconstitution in HIV-Infected Individuals after Initiation of Highly Active Antiretroviral Therapy

AIDS Research and Treatment ◽

10.1155/2011/743597 ◽

2011 ◽

Vol 2011 ◽

pp. 1-4 ◽

Cited By ~ 10

Author(s):

Samad Rasul ◽

Robert Delapenha ◽

Faria Farhat ◽

Jhansi Gajjala ◽

Syeda Mehreen Zahra

Keyword(s):

Antiretroviral Therapy ◽

Highly Active Antiretroviral Therapy ◽

Immune Reconstitution ◽

Immunological Response ◽

Signs And Symptoms ◽

Graves Disease ◽

Typically Develop ◽

Highly Active ◽

Inflammatory Syndrome ◽

Haart Therapy

Graves' disease after the initiation of highly active antiretroviral therapy (HAART) in certain HIV-1-infected individuals has been described as an immune reconstitution inflammatory syndrome (IRIS). This phenomenon should be suspected in individuals who present with clinical deterioration and a presentation suggestive of hyperthyroidism despite good virological and immunological response to HAART. Signs and symptoms of hyperthyroidism may be discrete or overt and typically develop 8–33 months after initiating therapy. One to two percent of HIV-infected patients can present with overt thyroid disease. Relatively few cases of Graves' IRIS have been reported in the literature to date. We describe four cases of Graves' IRIS in HIV-infected patients who were started on HAART therapy.

Download Full-text